4724-10-1

Basic information

• Product Name: Methyl 3,5-dihydroxyphenylacetate
• Synonyms: METHYL 3,5-DIHYDROXYPHENYLACETATE;Methyl 3,5-dihyroxyphenylacetate;3,5-Dihdyroxyphenylacetic acid methyl ester;Methyl 2-(3,5-dihydroxyphenyl)acetate;Benzeneacetic acid, 3,5-dihydroxy-, methyl ester;Methyl 3,5-dihydroxyphenylacetate 97%
• CAS NO: 4724-10-1
• Molecular Formula: C₉H₁₀O₄
• Molecular Weight: 182.17
• Product Categories: Aromatic Esters;C8 to C9;Carbonyl Compounds;Esters;Building Blocks;C8 to C9;Carbonyl Compounds;Chemical Synthesis;Organic Building Blocks
• Mol File: 4724-10-1.mol
• Article Data: 10

Chemical Properties

• Melting Point: 109-112 °C(lit.)
• Boiling Point: 333.289 °C at 760 mmHg
• Flash Point: 135.42 °C
• Appearance: /
• Density: 1.31 g/cm³
• Vapor Pressure: 7.13E-05mmHg at 25°C
• Refractive Index: 1.575
• PKA: 9.13±0.11(Predicted)
• CAS DataBase Reference: Methyl 3,5-dihydroxyphenylacetate(CAS DataBase Reference)
• NIST Chemistry Reference: Methyl 3,5-dihydroxyphenylacetate(4724-10-1)
• EPA Substance Registry System: Methyl 3,5-dihydroxyphenylacetate(4724-10-1)

Safety Data

• Hazard Codes: Xi
• Statements: 36/37/38
• Safety Statements: 26-36
• WGK Germany: 3
• HazardClass: IRRITANT
• Hazardous Substances Data: 4724-10-1(Hazardous Substances Data)

Usage

Uses

Methyl (3,5-Dihydroxyphenyl)acetate is a reagent in the synthesis of the fungal metabolites cytosporones A, C, J, K, and N .

General Description

Methyl 3,5-dihydroxyphenylacetate is a phenylacetic acid derivative. It is a known metabolite of Curvularia Siddiqui. It has been extracted from the culture mycelia of Curvularia lunata supported on culture medium (consisting of yeast, malt extract and glucose).

InChI:InChI=1/C9H10O4/c1-13-9(12)4-6-2-7(10)5-8(11)3-6/h2-3,5,10-11H,4H2,1H3

Upstream product

• 186581-53-3 diazomethane 
• 4670-09-1 2-(3,5-dihydroxyphenyl)acetic acid 
• 4670-10-4 (3,5-dimethoxyphenyl)acetic acid 
• 6512-25-0 dimethyl 2,4-dihydroxy-6-(2-methoxy-2-oxoethyl)benzene-1,3-dicarboxylate 
• 6512-32-9 methyl 2-(3,5-dimethoxyphenyl)acetate 
• 2150-37-0 methyl 3,5-dimethoxybenzoate 
• 6652-32-0 3,5-dimethoxybenzylchloride 
• 13388-75-5 3,5-dimethoxyphenylacetonitrile 
• 705-76-0 3,5-dimethoxybenzyl alcohol 
• 80457-61-0 methanesulfonyl 3,5-dibenzyloxybenzyl alcohol 
• 58604-84-5 (3',5'-dibenzyloxy)phenylacetonitrile 
• 24131-31-5 3,5-dibenzyloxybenzyl alcohol 
• 99-10-5 3,5-Dihydroxybenzoic acid 
• 58605-10-0 methyl 3,5-bis(benzyloxy)benzoate 

Downstream Products

• 855417-72-0 (3,5-dioxo-cyclohexyl)-acetic acid 
• 80457-68-7 2-(3,5-bisbenzyloxyphenyl)pent-2-ynoic acid 
• 80457-65-4 ethyl 2-(3,5-bisbenzyloxyphenyl)-2-methoxycarbonylacetate 
• 80457-67-6 ethyl methyl 3,5-bisbenzyloxyphenyl(prop-2-ynyl)malonate 
• 1056986-92-5 C₁₆H₁₂ClNO₄ 
• 425638-64-8 [3-(2-Triisopropylsilyloxy-ethoxy)-5-hydroxy-phenyl]-acetic Acid Methyl Ester 
• 934241-99-3 methyl {3-[2-chloro-4-(ethylsulfonyl)phenoxy]-5-hydroxyphenyl}acetate 
• 929094-12-2 (3-ethoxy-5-hydroxy-phenyl)-acetic acid methyl ester 
• 936758-51-9 [3-(tert-butyl-dimethyl-silanyloxy)-5-hydroxy-phenyl]-acetic acid methyl ester 
• 135388-00-0 methyl 1,3-bis(tert-butyldimethylsilyloxy)phenylacetate 

Relevant articles and documents

First total synthesis of medicinally important 3,4,7-trimethoxy-9,10-dihydrophenanthrene-1,5-diol

The first total synthesis was successfully achieved for biologically active 9,10-dihydrophenanthrene-1,5-diol. The key features of our synthetic approach are Perkin condensation, followed by bromination, palladium mediated intramolecular C-C bond coupling, and selective isopropyl ether cleavage. Synthesized compounds were purified and characterized by IR, 1HNMR, 13CNMR and HRMS/LC-MS.

Syntheses of cytosporones A, C, J, K, and N, metabolites from medicinal fungi

The syntheses of the fungal metabolites cytosporones A, (±)-C, and N are reported. And the syntheses of cytosporones J and K are described for the first time. The preparation of racemic cytosporone J and racemic cytosporone K, natural products containing

COMPOUNDS AND COMPOSITIONS AS PPAR MODULATORS

The invention provides compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with the activity of the Peroxisome Proliferator-Activated Receptor (PPAR) families.